Cargando…

Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis

INTRODUCTION: Acquired resistance to endocrine therapy (ET) remains a big challenge in the management of metastatic breast cancer (MBC). A novel therapeutic agent, histone deacetylase inhibitors (HDACi), targets the abnormal epigenetic modification and may overcome acquired resistance. However, HDAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Changjun, Lin, Yan, Zhu, Hanjiang, Zhou, Yidong, Mao, Feng, Huang, Xin, Sun, Qiang, Li, Chenggang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192957/ https://www.ncbi.nlm.nih.gov/pubmed/35712478 http://dx.doi.org/10.3389/fonc.2022.901152

Ejemplares similares

The Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients With Breast Cancer: A Systematic Review and Meta-Analysis
por: Wang, Changjun, et al.
Publicado: (2022)

Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials
por: Yang, Peipei, et al.
Publicado: (2023)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
por: Guo, Fengyi, et al.
Publicado: (2022)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
por: Selim, Omar, et al.
Publicado: (2023)

Evaluation of Histone Deacetylase Inhibitors as Radiosensitizers for Proton and Light Ion Radiotherapy
por: Johnson, Alicia M., et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Characterization of Histone Deacetylase Mechanisms in Cancer Development
por: Hai, Rihan, et al.
Publicado: (2021)

Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma
por: Meng, Wei, et al.
Publicado: (2018)

Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia
por: Pfeiffer, Matthias Manuel, et al.
Publicado: (2013)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
por: Wang, Hao, et al.
Publicado: (2021)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
por: Zhang, Juan, et al.
Publicado: (2021)

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors
por: Gordon, Michael S., et al.
Publicado: (2022)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
por: Wang, Changjun, et al.
Publicado: (2016)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
por: Yeon, Minjeong, et al.
Publicado: (2020)

Histone Deacetylase Inhibitor Trichostatin A Reduces Endothelial Cell Proliferation by Suppressing STAT5A-Related Gene Transcription
por: Li, Yize, et al.
Publicado: (2021)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
por: Shojaei, Farbod, et al.
Publicado: (2022)

High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors
por: Zhao, Wenxiu, et al.
Publicado: (2022)

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
por: Wang, Changjun, et al.
Publicado: (2020)

Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction
por: Burke, Brianna, et al.
Publicado: (2020)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma
por: Sundaramurthi, Husvinee, et al.
Publicado: (2022)

The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors
por: Jakobsen, Mie K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hd4v9v5i59k03ts4moco2tqiu0